罗沙司他与重组人促红素联合铁剂治疗肾性贫血及对微炎症因子的影响

Effect of roxadustat and recombinant human erythropoietin combined with iron on renal anemia and microinflammatory factors

目的探讨罗沙司他与重组人促红素联合铁剂治疗肾性贫血的疗效及对微炎症因子的影响。方法将2019年10月—2020年10月来院治疗的80例肾性贫血患者作为研究对象,按照随机数字表法分为对照组和观察组,对照组接受重组人促红素联合铁剂治疗,观察组接受罗沙司他治疗,对比2组患者治疗疗效、贫血指标、微炎症因子的变化。结果治疗后观察组治疗有效率为95.00%,显著高于对照组的80.00%,差异具有统计学意义(P<0.05);治疗后观察组血红蛋白(HGB)、红细胞计数(RBC)、铁蛋白(SF)均高于对照组,差异具有统计学意义(P<0.05);治疗后观察组C-反应蛋白(CRP)、白蛋白(ALB)和白细胞介素6(IL-6)均低于对照组,差异具有统计学意义(P<0.05)。结论罗沙司他治疗肾性贫血效果好于重组人促红素联合铁剂治疗,可有效缓解患者贫血症状,改善患者体内微炎症状态。

Objective To compare the effect of roxadustat and recombinant human erythropoietin combined with iron on renal anemia and its influence on microinflammatory factors.Methods 80 patients with renal anemia treated in our hospital from October 2019 to October 2020 were randomly divided into control group and observation group according to rardom number division.The control group was treated with recombinant human erythropoietin combined with iron,while the observation group was treated with roxadustat.The therapeutic efficacy,anemia indexes and changes of microinflammatory factors were compared between the two groups.Results After treatment,the effective rate of the observation group was 95.00%,which was significantly higher than that of the control group(80.00%,P<0.05).After treatment,the hemoglobin(HGB),red blood cell count(RBC)and ferritin(SF)in observation group were higher than those in control group,and the difference was statistically significant(P<0.05).After treatment,the levels of C-reactive protein(CRP),albumin(ALB)and interleukin-6(IL-6)in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion Roxadustat is better than recombinant human erythropoietin combined with iron in the treatment of renal anemia,which can effectively relieve anemia symptoms and improve the microinflammation in patients,and is worthy of clinical promotion.